PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1621688
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1621688
Non-opioid Pain Patch Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
The Global Non-opioid Pain Patch Market reached USD 828.3 million in 2023 and is projected to grow at a CAGR of 6.6% from 2024 to 2032. Non-opioid pain patches are transdermic devices designed to deliver medication directly through the skin, providing targeted pain relief without the risks associated with opioids. Effective in managing chronic, neuropathic, musculoskeletal, and post-surgical pain, these patches offer a safe alternative to opioid medications, addressing the need for non-addictive, effective pain management solutions. The market is propelled by increasing research and development in pain management, including initiatives like the NIH Heal Initiative, which focuses on advancing chronic pain treatment and reducing opioid use disorder (OUD) and overdose rates. Such programs are fostering the development of safer, opioid-free treatments, significantly boosting the demand for non-opioid pain patches.
Product-wise, the market includes lidocaine, diclofenac, methyl salicylate, capsaicin, ketoprofen, and other pain-relief patches. The lidocaine segment led the market in 2023 with revenues of USD 357 million, showing strong growth potential due to the escalating interest in opioid alternatives. The high rates of addiction and fatalities linked to opioid medications have pushed healthcare providers and patients toward safer options like lidocaine patches, which deliver localized pain relief without addiction risks. Regarding therapeutic application, the non-opioid pain patch market from the Chronic pain management held a significant 42.4% market share in 2023 and is expected to see notable growth.
Non-opioid patches have proven effective in managing chronic pain, often comparable to oral medications, with the added advantage of continuous, localized relief. Clinical studies underscore their utility, prompting greater adoption for long-term pain management. U.S. dominated the market, generating USD 244.3 million in revenue in 2023, and is anticipated to experience strong growth. Government regulations on opioid prescriptions, including FDA guidelines promoting non-opioid options, have fueled demand for pain patches containing lidocaine, diclofenac, and capsaicin for both chronic and acute pain.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $828.3 Million |
| Forecast Value | $1.5 Billion |
| CAGR | 6.6% |
Additionally, the U.S. has a growing elderly population, which experiences higher rates of musculoskeletal conditions, chronic joint pain, and arthritis-further driving the need for non-opioid pain management solutions.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing use of opioid prescriptions
- 3.2.1.2 Rising incidence of pain related disorders
- 3.2.1.3 Advantages offered by non-opioid pain patches over other forms of medications
- 3.2.1.4 Rising R&D in pain management treatments
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Side effects caused by prolonged use of non-opioid pain patches
- 3.2.2.2 Availability of alternative treatments
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 U.S.
- 3.4.2 Europe
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Reimbursement scenario
- 3.7 Pricing analysis
- 3.7.1 By region
- 3.7.2 By product
- 3.8 Consumer behavior analysis
- 3.9 Future market trends
- 3.10 Patent analysis
- 3.11 Profit margin analysis
- 3.12 Pipeline analysis
- 3.13 Clinical trial landscape
- 3.14 Gap analysis
- 3.15 Porter's analysis
- 3.16 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Lidocaine patches
- 5.3 Diclofenac patches
- 5.4 Methyl Salicylate patches
- 5.5 Capsaicin patches
- 5.6 Ketoprofen patches
- 5.7 Other patches
Chapter 6 Market Estimates and Forecast, By Therapeutic Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Chronic pain
- 6.3 Acute pain
- 6.4 Neuropathic pain
- 6.5 Musculoskeletal pain
- 6.6 Other therapeutic applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacies
- 7.3 Retail pharmacies
- 7.4 Online pharmacies
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 Acorda Therapeutics
- 9.2 AdhexPharma
- 9.3 Endo Pharmaceuticals
- 9.4 Glaxo SmithKline
- 9.5 Grunenthal
- 9.6 Hisamitsu Pharmaceutical
- 9.7 IBSA Institut Biochimique
- 9.8 Johnson & Johnson
- 9.9 Mylan (Viatris)
- 9.10 Nichiban
- 9.11 Pfizer
- 9.12 ProSolus
- 9.13 Sanofi
- 9.14 Teikoku Seiyaku
- 9.15 Teva Pharmaceuticals
